-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Lp5MZDL5lEl0bdPZw5cgIzSIFCb+crsH5lyRAhOfDpQ5jkiwconctOsAoh6CZQjn rAoXXgdB0GhRC2V4zVF2nQ== 0001104659-10-032965.txt : 20100608 0001104659-10-032965.hdr.sgml : 20100608 20100608170036 ACCESSION NUMBER: 0001104659-10-032965 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100603 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20100608 DATE AS OF CHANGE: 20100608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: THERAVANCE INC CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943265960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-30319 FILM NUMBER: 10885042 BUSINESS ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6508086000 MAIL ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: S. SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 8-K/A 1 a10-11598_18ka.htm 8-K/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 

 

FORM 8-K/A

 

 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): June 3, 2010

 

 

THERAVANCE, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

(State or Other Jurisdiction of
Incorporation)

 

000-30319

(Commission File Number)

 

94-3265960

(I.R.S. Employer Identification Number)

 

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

On April 30, 2010 Theravance, Inc. (the “Company”) filed a Periodic Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission to reflect the results of its 2010 Annual Meeting of Stockholders.  On June 3, 2010, the Company was informed by its transfer agent, Bank of New York Mellon, that due to a system error, the voting results previously reported for William D. Young were incorrect.  The voting results for Mr. Young reported in the Original 8-K were 52,843,922 votes “for” and 930,720 votes “withheld.”  The revised voting results for Mr. Young that Bank of New York Mellon provided to the Company on June 3, 2010 were 51,631,664 votes “for” and 2,142,978 votes “withheld.”  There were no changes to the voting results reported in the Original 8-K other than those for Mr. Young.  The Original 8-K is amended by this Form 8-K/A to reflect the final voting results from the Company’s 2010 Annual Meeting of Stockholders, as shown in Item 5.07 below.

 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

(a)           The Annual Meeting of Stockholders of Theravance, Inc. was held on April 27, 2010.

 

(b)           The table below presents the final results of the election to the Company’s board of directors.

 

 

 

Votes for

 

Votes withheld

 

Rick E Winningham

 

53,531,064

 

243,578

 

Jeffrey M. Drazan

 

35,871,470

 

17,903,172

 

Robert V. Gunderson, Jr.

 

52,818,471

 

956,171

 

Arnold J. Levine. Ph.D

 

37,123,809

 

16,650,833

 

Burton G. Malkiel, Ph.D.

 

53,620,797

 

153,845

 

Peter S. Ringrose, Ph.D.

 

53,644,830

 

129,812

 

William H. Waltrip

 

53,623,097

 

151,545

 

George M. Whitesides, Ph.D

 

52,114,309

 

1,660,333

 

William D. Young

 

51,631,664

 

2,142,978

 

 

 

The stockholders also approved the amendment and restatement of the Company’s 2004 Equity Incentive Plan. The table below presents the final voting results:

 

 

 

Affirmative
Votes

 

Negative
Votes

 

Votes
Withheld

 

Approval of amendment and restatement of 2004 Equity Incentive Plan

 

43,001,578

 

10,771,639

 

1,425

 

 

The stockholders also ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010. The table below presents the final voting results:

 

 

 

Affirmative
Votes

 

Negative
Votes

 

Votes
Withheld

 

Ratification of independent registered public accounting firm

 

58,892,703

 

184,450

 

4,111

 

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

THERAVANCE, INC.

 

 

 

 

Dated: June 8, 2010

By:

/s/ Bradford J. Shafer

 

 

 

 

 

Bradford J. Shafer

 

 

Senior Vice President and General Counsel

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----